Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

October 18, 2018

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

Read more

September 27, 2018

AELIX selected as one of the 20 most successful stories

Read more

July 25, 2018

AELIX partner in HIVACAR Consortium

Read more
More

Testimonials